BRENDA-Score, a Highly Significant, Internally and Externally Validated Prognostic Marker for Metastatic Recurrence: Analysis of 10,449 Primary Breast Cancer Patients.
BRENDA
breast cancer
follow up
prediction
risk
score
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
22 Jun 2021
22 Jun 2021
Historique:
received:
22
04
2021
revised:
16
06
2021
accepted:
17
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
3
7
2021
Statut:
epublish
Résumé
Background Current research in breast cancer focuses on individualization of local and systemic therapies with adequate escalation or de-escalation strategies. As a result, about two-thirds of breast cancer patients can be cured, but up to one-third eventually develop metastatic disease, which is considered incurable with currently available treatment options. This underscores the importance to develop a metastatic recurrence score to escalate or de-escalate treatment strategies. Patients and methods Data from 10,499 patients were available from 17 clinical cancer registries (BRENDA-project [
Identifiants
pubmed: 34206581
pii: cancers13133121
doi: 10.3390/cancers13133121
pmc: PMC8268855
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : German Federal Ministry of Education and Research
ID : BMBF-Grant-01ZP0505
Références
Oncol Lett. 2019 Feb;17(2):1505-1516
pubmed: 30675206
Breast Cancer Res Treat. 2015 Apr;150(3):621-9
pubmed: 25783184
Breast Cancer Res. 2017 May 22;19(1):58
pubmed: 28532503
BMC Cancer. 2019 Jan 18;19(1):90
pubmed: 30658597
Crit Rev Clin Lab Sci. 2020 Jan;57(1):54-72
pubmed: 31674269
Breast Cancer Res Treat. 2019 Apr;174(2):505-514
pubmed: 30560462
Pathol Oncol Res. 2020 Oct;26(4):2443-2450
pubmed: 32564262
J Cancer Epidemiol. 2014;2014:469251
pubmed: 24955090
BMC Cancer. 2013 Oct 21;13:487
pubmed: 24138748
Breast Cancer Res Treat. 2009 Apr;114(3):403-12
pubmed: 18421576
Br J Cancer. 1993 Nov;68(5):974-7
pubmed: 8217612
Oncotarget. 2017 Apr 25;8(17):27990-27996
pubmed: 28427196
J Natl Cancer Inst. 2020 Oct 1;112(10):979-988
pubmed: 32259259
Cochrane Database Syst Rev. 2016 May 27;(5):CD001768
pubmed: 27230946
J Cancer Res Clin Oncol. 2019 Jul;145(7):1823-1833
pubmed: 30927074
J Clin Oncol. 2012 May 20;30(15):1796-804
pubmed: 22508812
Br J Cancer. 1982 Mar;45(3):361-6
pubmed: 7073932
Breast Cancer Res Treat. 2013 Jul;140(1):63-71
pubmed: 23828499
J Cancer. 2018 May 25;9(12):2098-2106
pubmed: 29937928
Stat Med. 1996 Feb 28;15(4):361-87
pubmed: 8668867
Breast Cancer Res Treat. 2016 May;157(1):65-75
pubmed: 27116185
J Clin Oncol. 2010 Feb 10;28(5):718-22
pubmed: 20048188
Breast Cancer Res. 2019 Aug 13;21(1):92
pubmed: 31409418
Int J Cancer. 2019 Jan 15;144(2):263-272
pubmed: 30368776
Ann Transl Med. 2020 Apr;8(8):544
pubmed: 32411767
Arch Gynecol Obstet. 2017 Jan;295(1):211-223
pubmed: 27832352
Ann Transl Med. 2019 Oct;7(20):537
pubmed: 31807519
Cancer. 2016 Mar 15;122(6):908-16
pubmed: 26650715
Breast Cancer Res Treat. 2015 Aug;152(3):627-36
pubmed: 26162567
Value Health. 2020 Sep;23(9):1149-1156
pubmed: 32940232
Breast. 2017 Feb;31:318-324
pubmed: 27422453
Breast Cancer Res Treat. 2020 May;181(1):115-125
pubmed: 32193802
Breast Cancer Res Treat. 2013 Dec;142(3):579-90
pubmed: 24258258
Sci Rep. 2020 Jun 26;10(1):10459
pubmed: 32591580
BMC Cancer. 2019 Mar 14;19(1):230
pubmed: 30871490
J Natl Cancer Inst. 2019 Apr 1;111(4):339-341
pubmed: 30312420
Int J Radiat Oncol Biol Phys. 2016 Aug 1;95(5):1477-1484
pubmed: 27315662
Cancer Med. 2020 Nov;9(22):8540-8551
pubmed: 32945619
Pathol Oncol Res. 2008 Jun;14(2):113-5
pubmed: 18543079
Rev Med Brux. 2018;39(4):280-286
pubmed: 30320989
Biometrics. 2000 Jun;56(2):337-44
pubmed: 10877287